These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1627401)

  • 1. Early ovarian cancer and the icon trials.
    Ghersi D; Parmar MK; Stewart LA; Marsoni S; Williams CJ
    Eur J Cancer; 1992; 28A(6-7):1297. PubMed ID: 1627401
    [No Abstract]   [Full Text] [Related]  

  • 2. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
    Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum alone for chemotherapy for ovarian cancer?
    Johnston C
    Lancet; 1998 Nov; 352(9140):1567-8. PubMed ID: 9843097
    [No Abstract]   [Full Text] [Related]  

  • 5. Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?
    Sugiyama T
    Int J Clin Oncol; 2006 Jun; 11(3):163. PubMed ID: 16850120
    [No Abstract]   [Full Text] [Related]  

  • 6. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
    Williams CJ; Stewart L; Parmar M; Guthrie D
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):120-8. PubMed ID: 1411623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
    Omura GA; Brady MF
    Obstet Gynecol; 1993 Apr; 81(4):641-2. PubMed ID: 8459984
    [No Abstract]   [Full Text] [Related]  

  • 8. [Carboplatin/epirubicin/prednimustine (Sterecyt) as an adjuvant chemotherapy combination in ovarian cancer treated by radical surgery].
    Pickel H
    Gynakol Rundsch; 1989; 29 Suppl 2():357-8. PubMed ID: 2693256
    [No Abstract]   [Full Text] [Related]  

  • 9. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of polychemotherapy including cisplatin in patients with advanced ovarian cancer].
    Sablińska B; Wittczak-Ploch E; Drabik M
    Nowotwory; 1987; 37(1):50-5. PubMed ID: 3306608
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy for advanced ovarian cancer.
    Omura GA
    Lancet; 1987 Sep; 2(8560):689. PubMed ID: 2887974
    [No Abstract]   [Full Text] [Related]  

  • 12. [A case of neo-JP therapy in the treatment of ovarian carcinoma].
    Matsunami K; Takagi H; Hasegawa Y
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):153-5. PubMed ID: 7826073
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
    J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
    [No Abstract]   [Full Text] [Related]  

  • 16. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
    ten Bokkel Huinink WW; Dalesio O; Rodenhuis S; Dubbelman R; Hilton A; Franklin H; Koier I; van Tinteren H; van der Burg ME; van Oosterom AT
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):99-101. PubMed ID: 1411634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase III study of DWA2114R for ovarian cancer].
    Kato T; Yakushiji M; Nishimura H; Terashima Y; Sasaki H; Yamabe T; Yajima A; Fujimoto S; Hashimoto M; Nishiya I
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1285-93. PubMed ID: 1503482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, doxorubicin, and cyclophosphamide (PAC) in the treatment of mixed mesodermal tumor of the ovary.
    Wheelock J; Hancock K; Smith K
    Cancer Treat Rep; 1987 Dec; 71(12):1275-6. PubMed ID: 3690537
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of advanced ovarian carcinoma with cyclophosphamide, adriamycin and cisplatin: evaluation of the therapeutic response and analysis of the collateral effects].
    Facchini V; Gadducci A; Ceccarelli P; Dell'Arciprete T; Del Bravo B; Bartolini T; Fioretti P
    Ann Ostet Ginecol Med Perinat; 1986; 107(6):359-68. PubMed ID: 3566043
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Mucinous ovarian cancer.
    Omura GA
    Gynecol Oncol; 2005 Dec; 99(3):789; author reply 789-90. PubMed ID: 16125757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.